Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease. The post Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval appeared first on Investor's Business Daily.